A Study of Auxora in Patients With AKI and Injurious Lung Crosstalk (KOURAGE)
Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk With the Lung: A Randomized Control Trial (KOURAGE)
Sponsor: CalciMedica, Inc.
A PHASE2 clinical study on Acute Kidney Injury, this trial is ongoing. The trial is conducted by CalciMedica, Inc. and has accumulated 12 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CalciMedica, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .